


Supplementary Figure 6



Supplementary Figure 6. MET TKD mutations in NSCLC in cohort #1 and #2. (A) Flow chart of the NSCLC subgroup in cohort #1 (123 *MET* TKD mutations in 120 unique patients); (B) Prevalence of *MET* TKD mutations in NSCLC cases according to each dataset in cohort #1; (C) Lollipop plot of the oncogenic / likely oncogenic *MET* TKD mutations detected in NSCLC cases of cohort #1 (47 oncogenic / likely oncogenic *MET* TKD mutations in 44 unique patients); (D) Flow chart of the NSCLC subgroup in cohort #2 (590 *MET* TKD mutations in 586 unique patients); (E) Prevalence of *MET* TKD mutations in NSCLC cases according to cohort #2 (590 *MET* TKD mutations in 586 unique patients); (F) Lollipop plot of the oncogenic / likely oncogenic *MET* TKD mutations detected in NSCLC cases of cohort #2 (129 oncogenic / likely oncogenic *MET* TKD mutations in 129 unique patients).